Clinical Trial Update: Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous

View source ↗

Summary

ClinicalTrials.gov update reports a quality-of-life study in Greek hemodialysis patients treated with Zemplar Intravenous (paricalcitol) for secondary hyperpara…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar Intravenous (paricalcitol)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism | Status: COMPLETED | Results posted: 2014-07-24